Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1994-11-9
pubmed:abstractText
1. In rats, the atypical neuroleptic, clozapine, has been found to increase the hindlimb retraction time but not the forelimb retraction time, in the paw test. These parameters have predictive validity for the antipsychotic efficacy and extrapyramidal side-effects of drugs, respectively. The present study analysed to what extent drugs acting on adrenoceptors affect the behavioural effect of clozapine in the paw test. 2. The alpha 1-adrenoceptor agonist, ST 587 but not the peripherally working alpha 1-agonist, methoxamine, decreased the effect of clozapine on the hindlimb retraction time. The alpha 1-antagonist phenoxybenzamine increased this effect of clozapine, and blocked the effect of ST 587 on clozapine at low doses. Only the combination of phenoxybenzamine with clozapine produced an increase in forelimb retraction time. 3. The alpha 2-adrenoceptor agonist, clonidine, decreased the effect of clozapine on the hindlimb retraction time. This effect was neither antagonized by the alpha 2-antagonist rauwolscine nor by the alpha 1-antagonist phenoxybenzamine. Rauwolscine or the peripherally working alpha 2-antagonist L-659,066 did not influence the effect of clozapine on the hindlimb retraction time. The forelimb retraction time was not affected by any of the drug combinations. 4. In contrast to the beta 2-adrenoceptor agonist, clenbuterol, which was ineffective, the peripherally acting beta-agonist, (-)-isoprenaline, increased the effects of clozapine on the hindlimb retraction time. The beta-antagonist, (-)-propranolol as well as the peripherally acting beta-antagonist, nadolol decreased this effect of clozapine. Low doses of the peripherally acting beta 1-antagonist, atenolol, as well as low doses of the beta2-antagonist, ICI-118,551, decreased the effect of clozapine. A low dose of nadolol blocked the effect of (-)-isoprenaline on clozapine. Only the combination of clenbuterol with clozapine produced an increase in forelimb retraction time.5. It is concluded that blockade of central alpha l-adrenoceptors plays an important role in the effect of clozapine on the hindlimb retraction time. Furthermore, the effect of clozapine on the hindlimb retraction time is strongly modulated by peripheral beta 1- and/or beta 2-adrenoceptors. Given the predictive validity of the paw test, the presented data suggest that the alpha 1-adrenoceptor antagonist properties of clozapine are important for its therapeutic effects, but not for its lack of extrapyramidal side-effects.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-1358126, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-1418884, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-1678712, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2154119, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2421272, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2570359, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2822449, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2835476, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2863337, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2869639, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2879204, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2893411, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2894605, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2895008, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-2904633, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-3010073, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-3033200, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-3290950, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-3766793, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-3854, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6107617, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6108081, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6111465, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6113530, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6113964, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6128681, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6149136, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-6191142, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-7907518, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-8095900, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-8099741, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-8377842, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-8471132, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-945467, http://linkedlifedata.com/resource/pubmed/commentcorrection/7921601-959470
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
112
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
769-74
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:7921601-Adrenergic alpha-1 Receptor Agonists, pubmed-meshheading:7921601-Adrenergic alpha-1 Receptor Antagonists, pubmed-meshheading:7921601-Adrenergic alpha-2 Receptor Agonists, pubmed-meshheading:7921601-Adrenergic alpha-2 Receptor Antagonists, pubmed-meshheading:7921601-Adrenergic beta-Antagonists, pubmed-meshheading:7921601-Animals, pubmed-meshheading:7921601-Antipsychotic Agents, pubmed-meshheading:7921601-Basal Ganglia Diseases, pubmed-meshheading:7921601-Behavior, Animal, pubmed-meshheading:7921601-Central Nervous System, pubmed-meshheading:7921601-Clozapine, pubmed-meshheading:7921601-Disease Models, Animal, pubmed-meshheading:7921601-Drug Interactions, pubmed-meshheading:7921601-Male, pubmed-meshheading:7921601-Peripheral Nervous System, pubmed-meshheading:7921601-Rats, pubmed-meshheading:7921601-Rats, Wistar, pubmed-meshheading:7921601-Receptors, Adrenergic
pubmed:year
1994
pubmed:articleTitle
Peripheral and central adrenoceptor modulation of the behavioural effects of clozapine in the paw test.
pubmed:affiliation
Department of Psycho- and Neuropharmacology, University of Nijmegen, The Netherlands.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't